Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein
- PMID: 2832276
- DOI: 10.1007/978-3-642-72624-8_89
Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein
Abstract
By analogy to other retroviruses, the major envelope glycoprotein - gp120 - of HTLV-III/LAV is a probable target for neutralizing antibody. This antigen has been purified from H9 cells chronically infected with the HTLV-IIIB prototype strain. Several goats immunized with the gp120 produced antibodies that neutralized infection of H9 by the homologous virus isolate. These same sera failed to neutralize the divergent HTLV-IIIRF isolate. Individuals infected with HTLV-III/LAV commonly develop antibodies to gp120 which could be isolated using the gp120 antigen coupled to an immunoadsorbent resin. The antibody fraction that bound tightly to such a resin was found to neutralize the IIIB but not the RF isolate in a fashion similar to that of the goat anti-gp120 sera. However, the nonbinding fraction (effluent) from the resin also contained neutralizing activity which was able to block infection by both virus isolates with similar efficacy. Human antibodies to the other virus envelope gene product, the transmembrane gp41, were also affinity-purified utilizing the recombinant peptide 121, but they failed to influence infection by either virus isolate.
Similar articles
-
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709-13. doi: 10.1073/pnas.83.24.9709. Proc Natl Acad Sci U S A. 1986. PMID: 2432599 Free PMC article.
-
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82. doi: 10.1073/pnas.85.12.4478. Proc Natl Acad Sci U S A. 1988. PMID: 2454471 Free PMC article.
-
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.J Immunol. 1989 May 15;142(10):3612-9. J Immunol. 1989. PMID: 2469721
-
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6. doi: 10.1073/pnas.85.6.1932. Proc Natl Acad Sci U S A. 1988. PMID: 2450351 Free PMC article.
-
Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.Crit Rev Immunol. 1988;8(4):315-39. Crit Rev Immunol. 1988. PMID: 2850890 Review.
Cited by
-
Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells.J Exp Med. 1991 Apr 1;173(4):881-7. doi: 10.1084/jem.173.4.881. J Exp Med. 1991. PMID: 2007856 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources